FS, M., W, F., A, V., M, C., P, M., F, M., . . . A, O. (2025). Switching to subcutaneous administration may offer more profound remission compared to intensified intravenous therapy in patients with inflammatory bowel disease and partial response following induction with intravenous vedolizumab: The PRIVEDO study. Journal of Crohn's & colitis, 19(10), . https://doi.org/10.1093/ecco-jcc/jjaf175
Chicago Style (17th ed.) CitationFS, Macaluso, et al. "Switching to Subcutaneous Administration May Offer More Profound Remission Compared to Intensified Intravenous Therapy in Patients with Inflammatory Bowel Disease and Partial Response Following Induction with Intravenous Vedolizumab: The PRIVEDO Study." Journal of Crohn's & Colitis 19, no. 10 (2025). https://doi.org/10.1093/ecco-jcc/jjaf175.
MLA (9th ed.) CitationFS, Macaluso, et al. "Switching to Subcutaneous Administration May Offer More Profound Remission Compared to Intensified Intravenous Therapy in Patients with Inflammatory Bowel Disease and Partial Response Following Induction with Intravenous Vedolizumab: The PRIVEDO Study." Journal of Crohn's & Colitis, vol. 19, no. 10, 2025, https://doi.org/10.1093/ecco-jcc/jjaf175.
